ReviewHaemophilia : the official journal of the World Federation of Hemophilia
Monitoring Extended Half-Life Factor VIII and IX Concentrates: Performance in Routine Clotting-and Thrombin Generation Assays.
Review in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMonitoring extended half-life (EHL) factor (F) VIII and FIX products is complex, as discrepant results are obtained in different laboratory assays.
aimTo provide an overview on assay accuracy based on a re-assessment of previously published data as well as laboratory results of EHL spiking experiments for specific factor assays and thrombin generation (TG).
methodsPreviously published data on specific EHL-assay combination accuracy were re-assessed, applying uniform acceptable bias cutoffs at specific factor activity levels. Accuracy of EHL measurement was determined for six routinely used FVIII assays for spiked efmoroctocog alfa and rurioctocog alfa pegol as well as four FIX assays for spiked eftrenonacog alfa, albutrepenonacog alfa and nonacog bèta pegol. TG was performed on these samples to evaluate haemostatic potential.
resultsRe-assessment of previously published data showed insufficient accuracy for many EHL-assay combinations. Measurement results of nine previously undescribed EHL-assay combinations did not meet accuracy criteria for the entire tested factor activity range; results for other EHL-assay combinations were in many cases comparable to previous reports. TG on spiked efmoroctocog alfa and rurioctocog alfa pegol showed increased peak height (PH) and area under the curve (AUC) at higher factor activity level compared to diluted NPP FVIII. TG of eftrenonacog alfa was comparable to diluted NPP FIX but increased for albutrepenonacog alfa and nonacog bèta pegol.
conclusionAccuracy of many routine FVIII or FIX assays is insufficient, and selection of the correct test is essential for producing reliable results. The haemostatic potential of EHL may deviate from the labelled potency according to TG results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.